



## Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

April 2, 2024

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- [Inozyme Pharma, Inc.](#) (Nasdaq: INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Doug Treco, Ph.D., the company's chief executive officer and chairman of the board, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 from 10:15-10:55 a.m. ET.

A live webcast of the fireside chat can be accessed from the [Investor Relations](#) section of Inozyme's website under [events](#), where a replay of the event will also be available for a limited time.

### About Inozyme Pharma

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. Inozyme is developing INZ-701, an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation, which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

For more information, please visit <https://www.inozyme.com/> or follow Inozyme on [LinkedIn](#), [X \(formerly Twitter\)](#), and [Facebook](#).

### Contacts

#### Investors:

Inozyme Pharma  
Stefan Riley, Senior Director of IR and Corporate Communications  
(857) 330-8871  
[stefan.riley@inozyme.com](mailto:stefan.riley@inozyme.com)

#### Media:

SmithSolve  
Matt Pera  
(973) 886-9150  
[matt.pera@smithsolve.com](mailto:matt.pera@smithsolve.com)